RVL Pharmaceuticals plc (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The company is currently commercializing UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.
Headquarters: Bridgewater, NJ